Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Adding Bv improved survival for some Hodgkin patients

Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.

Key clinical point: Brentuximab vedotin (Bv), given before and after standard chemotherapy, improved survival in untreated Hodgkin lymphoma.

Major finding: Two-year PFS was 84% for patients treated additionally with Bv, compared with 50% historically for standard therapy.

Study details: A prospective phase 2 study involving 48 elderly patients with Hodgkin lymphoma.

Disclosures: Seattle Genetics supported the investigator-initiated trial. Dr. Evens reported consulting or advisory relationships with Seattle Genetics and several other companies.

Read the article.

Citation:

Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.